IP Library Granted Patent US 10,300,172
Granted Patent B2
US 10,300,172 · App. 15/339,834 · Granted May 28, 2019

Matrix for enhanced delivery of osteoinductive molecules in bone repair

Inventors: Eric Vanderploeg (Stoneham, MA); Howard Seeherman (Cambridge, MA); Christopher G. Wilson (Auburndale, MA); John Wozney (Hudson, MA); Christopher Todd Brown (Chelmsford, MA)
Assignee: Bioventus, LLC.
A61L27/56A61L24/0015A61L24/0036A61L24/0073A61L27/10A61L27/24A61L27/46A61L27/54A61L2300/252A61L2300/414A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,172
App. No.
15/339,834
Granted
May 28, 2019
Kind
B2
Abstract

Systems and methods for preparing osteoinductive synthetic bone grafts are provided in which a porous ceramic granule, which may be incorporated within a biocompatible matrix material, is loaded with an osteoinductive agent. Loading of granules is facilitated in some cases by the use of low-pH buffers and pre-treatments.

Claims (27)

1. A composition, comprising: a porous biocompatible polymer matrix having a plurality of macropores having an average size of about 100 μm to about 500 μm; admixed with a calcium ceramic granule having an average diameter of about 425 μm to about 800 μm and having an interconnected network of micropores defining at least one surface on an interior of the granule and wherein the calcium ceramic granule has a pH of less than 7, as measured in a slurry of said granules and water or another neutral, non-buffering solution.

2. The composition of claim 1 , further comprising an osteoinductive protein associated with the at least one interior surface, wherein a concentration of the osteoinductive protein near the centroid of the calcium ceramic granule is not less than about 33% of a concentration of the osteoinductive protein on the external surface of the calcium ceramic granules.

3. The composition of claim 1 wherein the porous biocompatible matrix additionally has a plurality of macropores with an average diameter of about 1 mm to 2 mm.

4. The composition of claim 1 where the porous biocompatible matrix is comprised of collagen.

5. The composition of claim 1 wherein the porous biocompatible matrix is comprised of a synthetic polymer.

6. The composition of claim 1 , wherein the composition has sufficient column strength to resist at least 50 kPa of pressure at 50% linear strain.

7. The composition of claim 2 , wherein said calcium ceramic granule retains at least 50% of the osteoinductive protein for a period of at least 7 days after implantation.

8. A method of treating a patient, comprising the steps of:

contacting a bony tissue of the patient with a composition, comprising:

a porous biocompatible matrix, the matrix including a plurality of macropores having an average size of about 100 μm to about 500 μm;

a calcium ceramic granule contacting the porous biocompatible matrix, said granule having an interconnected network of micropores defining at least one surface on an interior of the granule, wherein said granule has an average diameter of about 425 μm to about 800 μm and a pH of less than 7, as measured in a slurry of said granules and water or another neutral, non-buffering solution; and

an osteoinductive protein associated with the at least one surface on the interior of the granule, wherein the osteoinductive protein is distributed on a portion of the at least one surface near the centroid of the granule and on a portion of the at least one surface near the exterior of the granule.

9. The method of claim 8 , wherein the bony tissue is selected from the group consisting of a site of a traumatic injury to the bone and a vertebra.

10. The composition of claim 8 , wherein the calcium ceramic granule has a pH of 5.5 to 6.0.

11. The method of claim 8 , wherein the porous biocompatible matrix comprises collagen.

12. The method of claim 8 , wherein the porous biocompatible matrix comprises a synthetic polymer.

13. The method of claim 8 , wherein a concentration of the osteoinductive protein near the centroid of the calcium ceramic granule is not less than about 33% of a concentration of the osteoinductive protein on the external surface of the calcium ceramic granules.

14. The method of claim 8 , further comprising the step of wetting the composition with a solution comprising the osteoinductive protein, thereby associating the osteoinductive protein with the at least one surface.

15. A kit for treating a patient, comprising:

a carrier, comprising:

a porous biocompatible matrix, the matrix including a plurality of macropores having an average size of about 100 μm to about 500 μm; and

a calcium ceramic granule contacting the porous biocompatible matrix, said granule having an interconnected network of micropores defining at least one surface on an interior of the granule, wherein said granule has an average diameter of about 425 μm to about 800 μm and a pH of less than 7, as measured in a slurry of said granules and water or another neutral, non-buffering solution; and

a vessel holding an osteoinductive protein in a form in which the osteoinductive solution can be added to a fluid to form a solution, the solution being adapted to wet the carrier, thereby associating the osteoinductive protein with the at least one surface on the interior of the granule, thereby forming an implant.

16. The kit of claim 15 , wherein the porous biocompatible matrix additionally has a plurality of macropores with an average diameter of about 1 mm to 2 mm.

17. The kit of claim 15 , wherein the porous biocompatible matrix is comprised of collagen.

18. The kit of claim 15 , wherein the porous biocompatible matrix is comprised of a synthetic polymer.

19. The kit of claim 15 , wherein the implant has sufficient column strength to resist at least 50 kPa of pressure at 50% linear strain.

Assignments (4)
SECURITY INTEREST Recorded Aug 1, 2025
From: BIOVENTUS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071904/0465 →
RELEASE OF SECURITY INTEREST Recorded Aug 1, 2025
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BIOVENTUS LLC
Reel/Frame 071909/0861 →
SECURITY INTEREST Recorded Dec 13, 2019
From: BIOVENTUS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 051272/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2018
From: VANDERPLOEG, ERIC; SEEHERMAN, HOWARD; WILSON, CHRISTOPHER; WOZNEY, JOHN; BROWN, CHRISTOPHER T.
To: BIOVENTUS, LLC
Reel/Frame 044624/0099 →
Continuity (2)
Provisional Application 62248861 · Oct 30, 2015
Related Publication 20170209623A1 · Jul 27, 2017